AnGes, Inc. Logo

AnGes, Inc.

Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.

4563 | T

Overview

Corporate Details

ISIN(s):
JP3127700007
LEI:
Country:
Japan
Address:
茨木市彩都あさぎ七丁目7番15号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AnGes, Inc., founded in 1999, is a biopharmaceutical company dedicated to the research and development of gene-based medicines. The company focuses on becoming a global leader in genetic pharmaceuticals by developing innovative treatments that harness the power of genes. Its core pipeline includes Hepatocyte Growth Factor (HGF) gene therapy products for blood vessel regeneration, DNA vaccines based on plasmid DNA technology, and NF-kB decoy oligonucleotides. AnGes actively engages in clinical studies and forms global alliances and manufacturing collaborations to advance its therapeutic programs and make novel treatments accessible to patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-07 07:30
Registration Form
有価証券届出書(参照方式)
Japanese 244.5 KB
2025-08-13 06:50
Interim Report
確認書
Japanese 8.9 KB
2025-08-13 04:19
Interim Report
半期報告書-第27期(2025/01/01-2025/12/31)
Japanese 488.0 KB
2025-03-31 04:52
Post-Annual General Meeting Information
臨時報告書
Japanese 25.5 KB
2025-03-31 03:22
Governance Information
内部統制報告書-第26期(2024/01/01-2024/12/31)
Japanese 23.7 KB
2025-03-31 03:18
Registration Form
確認書
Japanese 8.9 KB
2025-03-31 03:17
Registration Form
有価証券報告書-第26期(2024/01/01-2024/12/31)
Japanese 1.5 MB
2024-09-03 06:05
Regulatory News Service
訂正有価証券届出書(参照方式)
Japanese 203.2 KB
2024-08-30 09:06
Registration Form
有価証券届出書(参照方式)
Japanese 381.2 KB
2024-08-14 02:28
Interim Report
確認書
Japanese 8.9 KB
2024-08-14 02:27
Interim Report
半期報告書-第26期(2024/01/01-2024/12/31)
Japanese 725.7 KB
2024-05-14 02:27
Report Publication Announcement
確認書
Japanese 8.9 KB
2024-05-14 02:25
Quarterly Report
四半期報告書-第26期第1四半期(2024/01/01-2024/03/31)
Japanese 457.7 KB
2024-03-29 01:45
Post-Annual General Meeting Information
臨時報告書
Japanese 24.0 KB
2024-03-29 01:43
Governance Information
内部統制報告書-第25期(2023/01/01-2023/12/31)
Japanese 23.6 KB

Automate Your Workflow. Get a real-time feed of all AnGes, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AnGes, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AnGes, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Ensysce Biosciences, Inc. Logo
Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.
United States of America
ENSC
Entera Bio Ltd. Logo
Developing oral versions of injectable drugs for osteoporosis, hypoparathyroidism, and obesity.
United States of America
ENTX
Entero Therapeutics, Inc. Logo
Develops targeted oral therapies for a range of gastrointestinal (GI) diseases.
United States of America
ENTO
Entrada Therapeutics, Inc. Logo
Developing intracellular therapeutics for rare neuromuscular diseases via its EEV™ platform.
United States of America
TRDA
Develops novel therapeutics and APIs for oncology, inflammation, and respiratory diseases.
South Korea
183490
Enzymatica AB Logo
Develops medical devices with patented enzyme technology to treat upper respiratory infections.
Sweden
ENZY
Developing alopecia therapies, skin regeneration products, and preclinical CRO services.
South Korea
446440
EQL Pharma AB Logo
Develops and sells cost-efficient niche generic medicines for the Nordic healthcare market.
Sweden
EQL
Equillium, Inc. Logo
Clinical-stage biotech creating therapies for severe autoimmune and inflammatory disorders.
United States of America
EQ
Erasca, Inc. Logo
Clinical-stage oncology company developing therapies targeting the RAS/MAPK pathway in cancer.
United States of America
ERAS

Talk to a Data Expert

Have a question? We'll get back to you promptly.